Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Clonal competition with alternating dominance in multiple myeloma.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL.

Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.

2.

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL.

Blood. 2012 Jul 12;120(2):376-85. doi: 10.1182/blood-2012-02-412783. Epub 2012 Mar 26.

3.

Latest advances and current challenges in the treatment of multiple myeloma.

Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K.

Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43. doi: 10.1038/nrclinonc.2012.15. Review.

PMID:
22349016
4.

Cancer statistics, 2012.

Siegel R, Naishadham D, Jemal A.

CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.

5.

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H.

Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8.

6.

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.

7.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Blood. 2012 Jan 5;119(1):7-15. doi: 10.1182/blood-2011-06-357038. Epub 2011 Oct 20.

8.

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.

Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. Epub 2011 Oct 12.

9.

The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.

Chiron D, Surget S, Maïga S, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Br J Haematol. 2012 Mar;156(5):679-83. doi: 10.1111/j.1365-2141.2011.08904.x. Epub 2011 Oct 11. No abstract available.

PMID:
21988294
10.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

11.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; NCRI Haematological Oncology Study Group.

Blood. 2011 Aug 4;118(5):1231-8. doi: 10.1182/blood-2011-02-338665. Epub 2011 Jun 7.

12.

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R.

Leukemia. 2011 Jun;25(6):1026-35. doi: 10.1038/leu.2011.53. Epub 2011 Apr 5.

13.

Initial genome sequencing and analysis of multiple myeloma.

Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR.

Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837.

14.

Multiple myeloma.

Palumbo A, Anderson K.

N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442. Review. No abstract available.

PMID:
21410373
15.

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.

Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z.

Nature. 2011 Feb 3;470(7332):124-8. doi: 10.1038/nature09658.

16.

Pathogenesis of myeloma.

Anderson KC, Carrasco RD.

Annu Rev Pathol. 2011;6:249-74. doi: 10.1146/annurev-pathol-011110-130249. Review.

PMID:
21261519
17.

Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Zingone A, Kuehl WM.

Semin Hematol. 2011 Jan;48(1):4-12. doi: 10.1053/j.seminhematol.2010.11.003. Review.

18.

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.

Steinbrunn T, Stühmer T, Gattenlöhner S, Rosenwald A, Mottok A, Unzicker C, Einsele H, Chatterjee M, Bargou RC.

Blood. 2011 Feb 10;117(6):1998-2004. doi: 10.1182/blood-2010-05-284422. Epub 2010 Dec 13.

19.

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD.

Blood. 2011 Jan 6;117(1):211-20. doi: 10.1182/blood-2010-07-298349. Epub 2010 Oct 25.

20.

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM.

Cancer Cell. 2010 Oct 19;18(4):367-81. doi: 10.1016/j.ccr.2010.09.005.

Supplemental Content

Support Center